Replies to post #1874 on Repros Therapeutics Inc (RPRX)

[io_io]

<"It is well understood that testosterone "feeds" prostate cancer..... there is no evidence that circulating testosterone causes prostate cancer to develop.">


But there IS evidence that AndroGel gives a far wider variation in levels of T to patients than Androxal does. It's right there in any RPRX presentation.

It wont be the AndroGel patient at the low-end of the T range that's more at risk for prostate cancer, or even the median patient.

But for those say, whose skin is unusually absorbent of the Gel, they will get far higher T levels than what Androxal would naturally give. Clearly the upper end of the unnatural T range are being put at risk.